Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

JUNO $33.42 3.7700 +12.72%
CCXI $5.87 0.6200 +11.81%
CLDX $4.23 0.4300 +11.32%
MRTX $6.78 0.5800 +9.35%
KITE $60.04 5.0600 +9.20%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IDRA $2.48 -0.1800 -6.77%
FATE $3.26 -0.1500 -4.40%
NKTR $17.35 -0.6800 -3.77%
THLD $1.14 -0.0400 -3.39%
ARGS $4.48 -0.1500 -3.24%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next > | Last >>

MDxHealth Gains Medi-Cal Approval for ConfirmMDx

(4-traders) Sept 6, 2016 - Opens testing access to the largest state-run health plan in the United States.
read article 

BD Submits Pre-Market Approval Application to FDA for BD Onclarity™ HPV Test

(StockWatch) Sept 6, 2016 - BD (Becton, Dickinson and Company), a leading global medical technology company, announced today that it has submitted a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the BD Onclarity™ HPV Assay, its human papillomavirus (HPV) test.
read article 

ICER Puts Hard-Fought Progress In Non-Small Cell Lung Cancer Treatment At Risk

(PhRMA/The Catalyst blog) Sept 1, 2016 - ICER’s draft evidence report on treatments for NSCLC indicates that they consider these life-changing treatments of low value.
read article 

German Pricing Rules Hit Eisai’s Halaven

(pharmaphorum [UK]) Sept 5, 2016 - Eisai may have to sell its Halaven (eribulin) at rock-bottom prices in its new advanced liposarcoma use in Germany after a cost-effectiveness body found it offered “no additional benefit” compared with standard care.
read article 

NICE Rejects Roche’s Melanoma Combo

(PharmaTimes [UK]) Sept 6, 2016 - Patients in England and Wales with a certain type of advanced skin cancer will not be getting routine access to Roche's Cotellic/Zelboraf combination on the NHS, after it was turned down by the National Institute for Health and Care Excellence.
read article 

Momenta Pulls The Plug On Pancreatic Cancer Drug

(BioPharma Dive) Sept 2, 2016 - Momenta Pharmaceuticals has decided to end development of necuparanib, an experimental drug for advanced pancreatic cancer and the biotech's lead clinical candidate, according to a regulatory filing submitted Thursday.
read article 

Karyopharm Sees Quicker U.S. Approval Path for Multiple Myeloma Drug

(TheStreet) Sept 6, 2016 - Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.
read article 

Even with Genetic Predisposition For Lung Cancer, Quitting Smoking Reduces Risk

(WUSTL) Sept 1, 2016 - A new study shows that even among smokers with a genetic predisposition to smoking heavily and developing lung cancer at a young age, the benefits of quitting are significant.
read press release 

Risky Health Behaviors Don’t Necessarily Stop With a Cancer Diagnosis

(Wall Street Journal) Sept 5, 2016 - A cancer diagnosis doesn’t automatically lead to an overhaul of unhealthy habits, says a study in the Journal of Cancer Survivorship.
read article (paid subscription required) 

There’s New Hope For Blood Cancers, And It Comes From Umbilical Cords

(Washington Post) Sept 5, 2016 - Many people who would have died for lack of a blood-type match can now be saved.
read article (free registration required) 

Study Opens Door To Targeted Treatments For Oesophageal Cancer

(Cancer Research UK) Sept 5, 2016 - Scientists have discovered that oesophageal cancer can be classified into three different subtypes, paving the way for testing targeted treatments tailored to patients’ disease for the first time.
read press release 

A Gene Defect As A Potential Gateway For Targeted Prostate Cancer Therapy

(EMBO [Heidelberg, Germany]) Sept 5, 2016 - The loss of CHD1, one of the most frequently mutated genes in prostate tumors, sensitizes human prostate cancer cells to different drugs, including PARP inhibitors. This suggests CHD1 as a potential biomarker for targeted prostate cancer therapy.
read press release 

Deaths from Ovarian Cancer Decline Worldwide Due to Oral Contraceptive Use

(ESMO) Sept 6, 2016 - Deaths from ovarian cancer fell worldwide between 2002 and 2012 and are predicted to continue to decline in the USA, European Union (EU) and, though to a smaller degree, in Japan by 2020, according to new research published in the leading cancer journal Annals of Oncology [1] today (Tuesday).
read press release 

New HIF-2 Kidney Cancer Therapy More Effective Than Current Treatment, Study Shows

(UT Southwestern Medical Center) Sept 5, 2016 - A new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer, researchers with the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center have found.
read press release 

Obesity Linked To Improved Survival In Kidney Cancer

(Dana-Farber Cancer Institute) Sept 5, 2016 - Obesity almost always increases cancer risk and worsens outcomes, but researchers led by scientists at Dana-Farber Cancer Institute report that overweight patients with advanced kidney cancer had significantly longer survival than those who were normal or underweight.
read press release 

Off-Label Cancer Drug Use -- Compendia in Need of Overhaul

(Medscape Medical News) Sept 6, 2016 - Cancer drugs are often used off label for indications that are not approved – but the system that covers the reimbursement for such use is inconsistent and needs to be overhauled, oncologists argue in an opinion piece published online August 25 in JAMA.
read article (free registration required) 

Lung Cancer Patients Whose Tumour Has Spread To The Brain Could Be Spared Radiotherapy

(Cancer Research UK) Sept 4, 2016 - Patients with non-small cell lung cancer which has spread to the brain could be spared whole brain radiotherapy as it makes little or no difference to how long they survive and their quality of life according to a Cancer Research UK-funded clinical trial published today in The Lancet.
read press release 

New Drugs for Ovarian Cancer Patients

(Wall Street Journal) Sept 5, 2016 - A new class of drugs could be a significant step forward in the treatment of ovarian cancer, one of the most lethal forms of the disease.
read article (paid subscription required) 

Major Trial: Forgo Whole-Brain RT in Lung Cancer

(Medscape Medical News) Sept 4, 2016 - Whole-brain radiotherapy is routinely used in lung cancer patients with multiple brain metastases, but a major trial shows no significant survival or QoL benefit.
read article (free registration required) 

The Secretive System For Vetting Cancer Drug Use Needs An Urgent Overhaul

(STAT/The Pharmalot View) Sept 6, 2016 - In the complicated world of medicine and money, the federal government relies on a handful of privately run directories to determine which cancer medicines it should pay for, and under which circumstances.
read article 

ASH Supports Changes to the NIH Human Stem Cell Research Guidelines and the Development of Chimeric Models

(ASH) Aug 31, 2016 - ASH submitted comments to the National Institutes of Health (NIH) supporting the proposed amendment to the guidelines for human stem cell research eligible for NIH funding and providing suggestions for the proposed scope of human-animal chimera research.
read article 

Insights on Lung Micro-Environment Explain Why Cancer Spreads to the Lungs

(OSUCCC - The James) Aug 25, 2016 - The same mechanisms that prevent people from having an inflammatory response to harmless environmental exposures in day-to-day life could also allow rogue cancer cells to spread to the lungs, according to new research from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
read press release 

Tobacco Industry Works to Block Rules on E-Cigarettes

(New York Times) Sept 2, 2016 - The e-cigarette and cigar industries have enlisted high-profile lobbyists and influential congressional allies in an attempt to stop the Food and Drug Administration from retroactively examining their products for public health risks or banning them from the market.
read article 

Merck Scraps Development Of Osteoporosis Drug Due To Stroke Risk

(Reuters) Sept 2, 2016 - Merck & Co Inc said it would stop developing its experimental osteoporosis drug after an independent analysis confirmed the treatment raises the risk of stroke.
read article 

Biogen's Alzheimer's Therapy Granted FDA Fast-Track Status

(NASDAQ/Dow Jones Newswires) Sept 1, 2016 - Biogen Inc. said its investigational therapy for the early stage of Alzheimer's disease was granted fast-track designation by the U.S. Food and Drug Administration, a designation intended to bring promising drugs for serious conditions to market faster.
read article